# Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy

> **NCT05985278** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** [ Lu-177]-Catalase

## Key facts

- **NCT ID:** NCT05985278
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05985278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05985278, "Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05985278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*